Author:
Zhang Yuqing,Jin De,Kang Xiaomin,Zhou Rongrong,Sun Yuting,Lian Fengmei,Tong Xiaolin
Abstract
Diabetic kidney disease (DKD), as the most common complication of diabetes mellitus (DM), is the major cause of end-stage renal disease (ESRD). Renal interstitial fibrosis is a crucial metabolic change in the late stage of DKD, which is always considered to be complex and irreversible. In this review, we discuss the pathological mechanisms of diabetic renal fibrosis and discussed some signaling pathways that are closely related to it, such as the TGF-β, MAPK, Wnt/β-catenin, PI3K/Akt, JAK/STAT, and Notch pathways. The cross-talks among these pathways were then discussed to elucidate the complicated cascade behind the tubulointerstitial fibrosis. Finally, we summarized the new drugs with potential therapeutic effects on renal fibrosis and listed related clinical trials. The purpose of this review is to elucidate the mechanisms and related pathways of renal fibrosis in DKD and to provide novel therapeutic intervention insights for clinical research to delay the progression of renal fibrosis.
Subject
Cell Biology,Developmental Biology
Reference203 articles.
1. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.;Agarwal;Nephrol. Dial. Transplant,2020
2. Activation of canonical wnt signalling is required for TGF-β-Mediated FIbrosis.;Akhmetshina;Nat. Commun.,2012
3. Phase 3, randomized, double-blind, active-comparator (Darbepoetin Alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan.;Akizawa;J. Am. Soc. Nephrol.
4. Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, Phase 3, multicenter, open-label study.;Akizawa;Ther. Apher. Dial.
5. Diabetic kidney disease: challenges, progress, and possibilities.;Alicic;Clin. J. Am. Soc. Nephrol. CJASN,2017
Cited by
109 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献